This SBIR project aims to develop hyperimmune human polyclonal antibody that neutralizes the toxic activity of staphylococcal enterotoxin B (SEB) as treatment for toxic shock induced by SEB disseminated as aerosol in a biowarfare scenario. The primary goal of Phase I was to demonstrate the feasibility of therapeutic intervention with immunoglobulin enriched with antibodies against SEB. Feasibility of the approach was demonstrated in cellular assays and a mouse model of ...
Reports by Corporate Author
